Table 2.
Characteristics of with T2DM and a subgroup of people using SGLT2 inhibitors in the real world compared with those in the EMPA-REG trial
| Characteristic | RCGP RSC total T2DM group (N = 60,327) | RCGP RSC SGLT2 user group (N = 1642) | EMPA-REG trial participants* (N = 4687) |
|---|---|---|---|
| Age (years) | 66.1 (±13.9) | 58.1 (±10.4) | 63.1 (±8.6) |
| Male | 33,535 (55.6) | 966 (58.8) | 3336 (71.2) |
| Race | |||
| White | 42,284 (70.1) | 1194 (72.2) | 3403 (72.6) |
| Asian | 5706 (9.5) | 155 (9.4) | 1006 (21.5) |
| Black | 2648 (4.4) | 40 (2.4) | 237 (5.1) |
| Other | 1109 (1.8) | 24 (1.5) | 36 (0.8) |
| Missing | 8580 (14.2) | 229 (13.9) | 5 (0.1) |
| BMI (kg/m2) | 30.7 (±6.5) | 34.0 (±6.4) | 30.6 (±5.3) |
| BMI not recorded | 1284 (2.1) | 9 (0.5) | 0 (0.0) |
| SBP (mmHg) | 132.0 (±14.7) | 130.2 (±13.4) | 135.3 (±16.9) |
| DBP (mmHg) | 75.0 (±9.6) | 76.0 (±8.6) | 76.6 (±9.7) |
| BP not recorded | 221 (0.4) | 2 (0.1) | 0 (0.0) |
| Diagnosed hypertension | 35,659 (59.1) | 901 (54.9) | NR |
| Uncontrolled hypertension† | 16,950 (28.1) | 373 (22.7) | NR |
| eGFR <60 ml/min/1.73 m2 | 11,167 (18.5) | 76 (4.6) | 0 (0.0) |
| Duration of diabetes | |||
| ≤1 years | 5320 (8.8) | 45 (2.7) | 128 (2.7) |
| >1–5 years | 17,911 (29.7) | 314 (19.1) | 712 (15.2) |
| >5–10 years | 18,963 (31.4) | 604 (36.8) | 1175 (25.1) |
| >10 years | 18,133 (30.1) | 679 (41.4) | 2672 (57.0) |
| Other glucose-lowering therapy | |||
| Metformin | 35,146 (58.3) | 1416 (30.2) | 3459 (73.8) |
| Insulin | 8128 (13.5) | 447 (9.5) | 2252 (48.0) |
| Sulfonylurea | 14,765 (24.5) | 800 (17.1) | 2014 (43.0) |
| Dipeptidyl peptidase-4 inhibitor | 7236 (12.0) | 605 (12.9) | 529 (11.3) |
| Thiazolidinedione | 1875 (3.1) | 144 (3.1) | 198 (4.2) |
| Glucagon-like peptide-1 agonist | 1983 (3.3) | 360 (7.7) | 126 (2.7) |
| Monotherapy | 21,284 (35.3) | 89 (5.5) | 1380 (29.4) |
| Dual therapy | 11,375 (18.9) | 448 (27.5) | 2259 (48.2) |
Data are presented as n (%) or mean (SD)
BMI body mass index, DBP diastolic blood pressure, eGFR estimated glomerular filtration rate, NR not reported, SBP systolic blood pressure, SD standard deviation
* Pooled empagliflozin participants (10 and 25 mg doses)
†Most recent systolic blood pressure ≥140 mmHg